Shigeki Kashimoto

848 total citations
21 papers, 733 citations indexed

About

Shigeki Kashimoto is a scholar working on Molecular Biology, Oncology and Small Animals. According to data from OpenAlex, Shigeki Kashimoto has authored 21 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Small Animals. Recurrent topics in Shigeki Kashimoto's work include Bioactive Compounds and Antitumor Agents (4 papers), Cancer therapeutics and mechanisms (4 papers) and Veterinary medicine and infectious diseases (4 papers). Shigeki Kashimoto is often cited by papers focused on Bioactive Compounds and Antitumor Agents (4 papers), Cancer therapeutics and mechanisms (4 papers) and Veterinary medicine and infectious diseases (4 papers). Shigeki Kashimoto collaborates with scholars based in Japan, United Kingdom and United States. Shigeki Kashimoto's co-authors include Yuji Sato, Katsumi Chiba, Shinichi Nakamura, Katsuhisa Nakata, Masaaki Yamada, Hiroaki Yoshida, Shiro Kato, Masaaki Sawa, Hironori Kinoshita and Tsuyoshi Kojima and has published in prestigious journals such as Nature Communications, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Shigeki Kashimoto

21 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shigeki Kashimoto Japan 14 339 243 185 118 79 21 733
Francesca Blasco Switzerland 14 426 1.3× 222 0.9× 145 0.8× 44 0.4× 12 0.2× 20 897
Janet S. Macpherson United Kingdom 16 385 1.1× 119 0.5× 333 1.8× 69 0.6× 7 0.1× 30 861
Santwana Kar United States 9 136 0.4× 110 0.5× 95 0.5× 57 0.5× 29 0.4× 11 372
Vincent Galullo United States 10 468 1.4× 229 0.9× 182 1.0× 41 0.3× 5 0.1× 10 724
Tamara Delaine Sweden 15 604 1.8× 165 0.7× 205 1.1× 548 4.6× 20 0.3× 21 1.3k
Saiqi Wang China 19 582 1.7× 462 1.9× 338 1.8× 74 0.6× 6 0.1× 56 1.3k
Diane K. Luci United States 13 488 1.4× 182 0.7× 159 0.9× 58 0.5× 6 0.1× 19 940
Senji Hori Japan 11 456 1.3× 236 1.0× 255 1.4× 24 0.2× 14 0.2× 20 761
Monish Jain United States 9 181 0.5× 169 0.7× 60 0.3× 42 0.4× 9 0.1× 17 525
Yu‐Shan Wu Taiwan 14 259 0.8× 77 0.3× 215 1.2× 19 0.2× 16 0.2× 45 516

Countries citing papers authored by Shigeki Kashimoto

Since Specialization
Citations

This map shows the geographic impact of Shigeki Kashimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigeki Kashimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigeki Kashimoto more than expected).

Fields of papers citing papers by Shigeki Kashimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shigeki Kashimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigeki Kashimoto. The network helps show where Shigeki Kashimoto may publish in the future.

Co-authorship network of co-authors of Shigeki Kashimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Shigeki Kashimoto. A scholar is included among the top collaborators of Shigeki Kashimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shigeki Kashimoto. Shigeki Kashimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kiyoi, Takao, et al.. (2021). Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry. 64(19). 14129–14141. 14 indexed citations
2.
Sugano, Teppei, Mari Masuda, Fumitaka Takeshita, et al.. (2020). Pharmacological blockage of transforming growth factor-β signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. British Journal of Cancer. 124(1). 228–236. 20 indexed citations
3.
Kashimoto, Shigeki, et al.. (2018). Abstract B152: CB1763, a highly selective, novel non-covalent BTK inhibitor, targeting ibrutinib-resistant BTK C481S mutant. Molecular Cancer Therapeutics. 17(1_Supplement). B152–B152. 7 indexed citations
4.
Uno, Yuko, Hideki Moriyama, Shigeki Kashimoto, et al.. (2018). Abstract B146: A novel TNIK inhibitor potently downregulates cancer stem cell population through attenuation of Wnt signaling. Molecular Cancer Therapeutics. 17(1_Supplement). B146–B146. 2 indexed citations
5.
Masuda, Mari, Yuko Uno, Naomi Ohbayashi, et al.. (2016). TNIK inhibition abrogates colorectal cancer stemness. Nature Communications. 7(1). 12586–12586. 128 indexed citations
6.
Uno, Yuko, Hideki Moriyama, Shigeki Kashimoto, et al.. (2013). Abstract B265: Targeting Wnt signaling: Discovery and characterization of novel thiazole-based Traf2- and NCK-interacting kinase (TNIK) inhibitors.. Molecular Cancer Therapeutics. 12(11_Supplement). B265–B265. 3 indexed citations
7.
Kashimoto, Shigeki, et al.. (2010). [In vivo activity of liposomal amphotericin B against Exophiala dermatitidis in a murine lethal infection model].. PubMed. 63(3). 265–72. 3 indexed citations
8.
Hirokawa, Yoshimi, Hironori Kinoshita, Tomoyuki Tanaka, et al.. (2008). Pleuromutilin derivatives having a purine ring. Part 2: Influence of the central spacer on the antibacterial activity against Gram-positive pathogens. Bioorganic & Medicinal Chemistry Letters. 19(1). 170–174. 29 indexed citations
9.
Hirokawa, Yoshimi, Hironori Kinoshita, Tomoyuki Tanaka, et al.. (2008). Pleuromutilin derivatives having a purine ring. Part 1: New compounds with promising antibacterial activity against resistant Gram-positive pathogens. Bioorganic & Medicinal Chemistry Letters. 18(12). 3556–3561. 33 indexed citations
10.
Hoch, Ute, Jennifer Lynch, Yuji Sato, et al.. (2008). Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemotherapy and Pharmacology. 64(1). 53–65. 52 indexed citations
11.
Hirokawa, Yoshimi, Hironori Kinoshita, Tomoyuki Tanaka, et al.. (2008). Pleuromutilin derivatives having a purine ring. Part 3: Synthesis and antibacterial activity of novel compounds possessing a piperazine ring spacer. Bioorganic & Medicinal Chemistry Letters. 19(1). 175–179. 34 indexed citations
12.
Hirokawa, Yoshimi, Hironori Kinoshita, Tomoyuki Tanaka, et al.. (2008). Water-Soluble Pleuromutilin Derivative with Excellent in Vitro and in Vivo Antibacterial Activity against Gram-Positive Pathogens. Journal of Medicinal Chemistry. 51(7). 1991–1994. 28 indexed citations
13.
Sato, Yuji, et al.. (2004). Synthesis and structure–activity relationships of 3-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines as novel antitumor agents. Bioorganic & Medicinal Chemistry Letters. 14(12). 3189–3193. 47 indexed citations
14.
Kashimoto, Shigeki, et al.. (2002). A study of brominated compound release from appliance-recycling facility. Organohalogen compounds. 56. 189–192. 9 indexed citations
15.
16.
Kashimoto, Shigeki, et al.. (1994). Effect of Acid Rain to Heavy Metal Leaching from Municipal Solid Waste Ash.. Journal of Environmental Conservation Engineering. 23(3). 159–164. 2 indexed citations
17.
Nakamura, Shinichi, et al.. (1991). Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.. Cancer Research. 51(1). 215–21. 18 indexed citations
18.
Nakamura, Shinichi, Katsuhisa Nakata, Shigeki Kashimoto, Hiroaki Yoshida, & Masaaki Yamada. (1986). Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.. PubMed. 77(8). 767–73. 82 indexed citations
19.
Nakamura, Shinichi, et al.. (1984). ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF AT-2266 IN EXPERIMENTAL ANIMALS. 32(3). 86–94. 11 indexed citations
20.
Nakamura, Shinichi, et al.. (1983). Pharmacokinetics of AT-2266 Administered Orally to Mice, Rats, Dogs, and Monkeys. Antimicrobial Agents and Chemotherapy. 24(1). 54–60. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Blasco Breakdown of academic impact, for papers by Janet S. Macpherson Breakdown of academic impact, for papers by Santwana Kar Breakdown of academic impact, for papers by Vincent Galullo Breakdown of academic impact, for papers by Tamara Delaine Breakdown of academic impact, for papers by Saiqi Wang Breakdown of academic impact, for papers by Diane K. Luci Breakdown of academic impact, for papers by Senji Hori Breakdown of academic impact, for papers by Monish Jain Breakdown of academic impact, for papers by Yu‐Shan Wu
Rankless by CCL
2026